Logo image of LAB

STANDARD BIOTOOLS INC (LAB) Stock Fundamental Analysis

NASDAQ:LAB - Nasdaq - US34385P1084 - Common Stock - Currency: USD

1.35  -0.04 (-2.88%)

After market: 1.37 +0.02 (+1.48%)

Fundamental Rating

3

Overall LAB gets a fundamental rating of 3 out of 10. We evaluated LAB against 57 industry peers in the Life Sciences Tools & Services industry. LAB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, LAB is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LAB had negative earnings in the past year.
LAB had a negative operating cash flow in the past year.
In the past 5 years LAB always reported negative net income.
LAB had a negative operating cash flow in each of the past 5 years.
LAB Yearly Net Income VS EBIT VS OCF VS FCFLAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

The Return On Assets of LAB (-25.03%) is worse than 66.67% of its industry peers.
With a Return On Equity value of -34.86%, LAB perfoms like the industry average, outperforming 40.35% of the companies in the same industry.
Industry RankSector Rank
ROA -25.03%
ROE -34.86%
ROIC N/A
ROA(3y)-31.11%
ROA(5y)-26.82%
ROE(3y)-63.68%
ROE(5y)-54.27%
ROIC(3y)N/A
ROIC(5y)N/A
LAB Yearly ROA, ROE, ROICLAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

LAB has a Gross Margin of 48.57%. This is comparable to the rest of the industry: LAB outperforms 54.39% of its industry peers.
In the last couple of years the Gross Margin of LAB has declined.
LAB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.69%
GM growth 5Y-2.74%
LAB Yearly Profit, Operating, Gross MarginsLAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150

More info and screens

4

2. Health

2.1 Basic Checks

LAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LAB has been increased compared to 1 year ago.
Compared to 5 years ago, LAB has more shares outstanding
LAB has a worse debt/assets ratio than last year.
LAB Yearly Shares OutstandingLAB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
LAB Yearly Total Debt VS Total AssetsLAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

LAB has an Altman-Z score of -0.56. This is a bad value and indicates that LAB is not financially healthy and even has some risk of bankruptcy.
LAB has a worse Altman-Z score (-0.56) than 73.68% of its industry peers.
LAB has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of LAB (0.00) is better than 78.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.56
ROIC/WACCN/A
WACC11.29%
LAB Yearly LT Debt VS Equity VS FCFLAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

LAB has a Current Ratio of 3.76. This indicates that LAB is financially healthy and has no problem in meeting its short term obligations.
LAB's Current ratio of 3.76 is fine compared to the rest of the industry. LAB outperforms 61.40% of its industry peers.
A Quick Ratio of 3.41 indicates that LAB has no problem at all paying its short term obligations.
LAB has a Quick ratio of 3.41. This is in the better half of the industry: LAB outperforms 63.16% of its industry peers.
Industry RankSector Rank
Current Ratio 3.76
Quick Ratio 3.41
LAB Yearly Current Assets VS Current LiabilitesLAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 10.13% over the past year.
Looking at the last year, LAB shows a very strong growth in Revenue. The Revenue has grown by 48.22%.
LAB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.21% yearly.
EPS 1Y (TTM)10.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.07%
Revenue 1Y (TTM)48.22%
Revenue growth 3Y-8.34%
Revenue growth 5Y-1.21%
Sales Q2Q%77.27%

3.2 Future

Based on estimates for the next years, LAB will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.57% on average per year.
Based on estimates for the next years, LAB will show a very strong growth in Revenue. The Revenue will grow by 25.15% on average per year.
EPS Next Y38.21%
EPS Next 2Y31.86%
EPS Next 3Y23.71%
EPS Next 5Y18.57%
Revenue Next Year66.21%
Revenue Next 2Y34.72%
Revenue Next 3Y29.6%
Revenue Next 5Y25.15%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LAB Yearly Revenue VS EstimatesLAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
LAB Yearly EPS VS EstimatesLAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LAB. In the last year negative earnings were reported.
Also next year LAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LAB Price Earnings VS Forward Price EarningsLAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LAB Per share dataLAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as LAB's earnings are expected to grow with 23.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.86%
EPS Next 3Y23.71%

More info and screens

0

5. Dividend

5.1 Amount

LAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STANDARD BIOTOOLS INC

NASDAQ:LAB (2/20/2025, 8:00:02 PM)

After market: 1.37 +0.02 (+1.48%)

1.35

-0.04 (-2.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-30 2024-10-30/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners72.07%
Inst Owner ChangeN/A
Ins Owners1.76%
Ins Owner Change-0.41%
Market Cap502.55M
Analysts82.86
Price Target3.14 (132.59%)
Short Float %3.52%
Short Ratio7.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.39%
Min EPS beat(2)-39.78%
Max EPS beat(2)22.99%
EPS beat(4)1
Avg EPS beat(4)-60.77%
Min EPS beat(4)-135.88%
Max EPS beat(4)22.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-7.53%
Min Revenue beat(2)-23.66%
Max Revenue beat(2)8.6%
Revenue beat(4)2
Avg Revenue beat(4)-1.24%
Min Revenue beat(4)-23.66%
Max Revenue beat(4)12.08%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.63%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.22
P/FCF N/A
P/OCF N/A
P/B 1.03
P/tB 1.4
EV/EBITDA N/A
EPS(TTM)-0.71
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.42
BVpS1.31
TBVpS0.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.03%
ROE -34.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.57%
FCFM N/A
ROA(3y)-31.11%
ROA(5y)-26.82%
ROE(3y)-63.68%
ROE(5y)-54.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.69%
GM growth 5Y-2.74%
F-Score5
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.05%
Cap/Sales 3.24%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.76
Quick Ratio 3.41
Altman-Z -0.56
F-Score5
WACC11.29%
ROIC/WACCN/A
Cap/Depr(3y)43.1%
Cap/Depr(5y)45.04%
Cap/Sales(3y)5.58%
Cap/Sales(5y)5.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.07%
EPS Next Y38.21%
EPS Next 2Y31.86%
EPS Next 3Y23.71%
EPS Next 5Y18.57%
Revenue 1Y (TTM)48.22%
Revenue growth 3Y-8.34%
Revenue growth 5Y-1.21%
Sales Q2Q%77.27%
Revenue Next Year66.21%
Revenue Next 2Y34.72%
Revenue Next 3Y29.6%
Revenue Next 5Y25.15%
EBIT growth 1Y-73.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.19%
EBIT Next 3Y25.42%
EBIT Next 5Y30.85%
FCF growth 1Y-83.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-85.84%
OCF growth 3YN/A
OCF growth 5YN/A